PHARMACEUTICAL INDUSTRY
Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA
Following an inspection from September 7 to September 15, 2026, the US FDA granted Apitoria Pharma, a subsidiary of Aurobindo Pharma, a Voluntary Action Indicated classification. This classification indicates that although objectionable conditions were found in the Telangana manufacturing facility, the absence of immediate regulatory action allows the company to address the issues through voluntary corrective measures.
India drawing up list of export snags in South Asia
India is identifying regulatory and market-access barriers in seven South Asian countries to expand exports and reach its $1-trillion target. Merchandise exports to these markets fell 1.3% to $25.7 billion in FY26. The government is examining certification delays, tariffs and product standards while exploring opportunities in chemicals, pharmaceuticals and textiles.
Q2 Earnings Scorecard: Which sectors outperformed and which fell behind?
The September quarter results indicate strong revenue and profit growth in sectors like automobiles and banking. In contrast, sectors such as IT and pharmaceuticals showed weakness amid inflationary pressures. Automobile sector leaders like Maruti Suzuki and Bajaj Auto reported significant growth in sales and exports. L&T's orders surged, while the cement sector faced challenges with fluctuating prices.
Sebi approves 6 IPOs including Mahanadi Coalfields, Veritas Finance and Sagar Defence. Check details
Sebi has granted approval for initial public offerings from six companies across various sectors. Companies like Mahanadi Coalfields and Sagar Defence Engineering are set to enter the stock market soon. The IPOs include both offers for sale and fresh issue components to raise significant funds. These approvals come amid increasing investor interest in diverse industries such as defence and pharmaceuticals.
Charting the global economy: Job growth in US tops all forecasts
US employment rose significantly last month, with the jobless rate declining to 4.1%, indicating robust economic activity. Labor productivity increased sharply in the third quarter, reflecting business adaptation to rising costs and greater efficiency.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
Piyush Goyal to visit Egypt with big business delegation; India eyes trade, investment partnerships
Commerce Minister Piyush Goyal will visit Egypt next week with a large business delegation to explore investment and collaboration in sectors including startups, fintech, pharmaceuticals and automobile components. The visit comes as India seeks to deepen its strategic engagement with West Asia and position Egypt as a gateway to African, Arab and European markets.
Bayer signs MoU with Karnataka government for ₹200 crore manufactuing facility near Bengaluru
Bayer Science and Innovation signed a Memorandum of Understanding with the Karnataka government to establish a manufacturing facility. The investment is worth ₹200 crore and is expected to create around 220 jobs. The agreement was signed in the presence of Large and Medium Industries Minister M. B. Patil. Bayer intends to break ground before the Global Investor's Meet scheduled for April 2027.
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts
In the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attention one way or another, there could well be some more action against Iran, changing the mood again in a single afternoon. So, the improvement in sentiment is real, but it is also fragile.
FDA flags persistent data-integrity lapses, insanitary conditions at Indian drug facilities
The US FDA continues to identify serious data integrity issues in Indian pharmaceutical manufacturing facilities. During inspections, inspectors found discarded documents related to key manufacturing processes, highlighting compliance concerns. To ensure safe medicines, drugmakers are urged to scrutinize their supply chains and monitor suppliers effectively. Additionally, human errors contributed significantly to production incidents, affecting operations and batch release timelines.
Stocks in news: Bharti Airtel, LIC, Titan, ONGC, Bharti Hexacom, Glenmark Pharma and Astral
Indian equity markets continued their upward trend, highlighted by the Nifty 50 gaining 576 points. Bharti Airtel, LIC, and Titan Company reported strong profit increases for the September quarter. ONGC also posted a substantial rise in consolidated profit compared to last year. In contrast, Glenmark Pharmaceuticals faced a significant decline in net profit this quarter. Overall, corporate developments are influencing investor sentiment as markets react to earnings reports.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Alkem Laboratories appoints Amrut Naik as CEO
Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
High Court restrains NPPA from action against AstraZeneca
The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.
Stocks in news: Reliance Industries, Jio Platforms, M&M, CDSL, ITC, NTPC, IOCL and Hero MotoCorp
Indian equity benchmarks closed higher on Friday, with significant gains recorded in the Nifty 50 and BSE Sensex. Several major companies, including Reliance Industries and Jio Platforms, published positive quarterly earnings results. Reliance Industries saw a 41% increase in net profit, supported by strong performances in various sectors. Other companies like Sun Pharma and Indian Oil Corporation also reported significant changes in their net profits.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: Report
Indian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision followed the discovery of failures in the company's quality management system. A joint inspection cited lapses that affected drug safety and quality, leading to a recall of several eye-drop brands. Significant adverse cases have raised concerns regarding product contamination, prompting further investigation.
Load More
